$1.18+3.1%Nov 13 close
The latest quarter (ended September 30, 2026) is from Tvardi Therapeutics’s earnings press release of November 13, 2026. It will be replaced by the official quarterly report (10-Q) once Tvardi Therapeutics files it.
The quarter ending March 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toMar 31, 2025 | 3 months toMar 31, 2024 | Change |
|---|---|---|---|
| Total Revenue | $2.6M | $2.1M | +20.33% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Tvardi Therapeutics, Inc. reported on November 13, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases with significant unmet need. STAT3 is a central mediator across critical signaling pathways that drive immune dysregulation, inflammation, and proliferation. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The Company has completed a Phase 1 healthy volunteer study of TTI-109 and plans to initiate clinical trials of TTI-109 in ulcerative colitis pending IND clearance and the availability of additional funding. The Company is also conducting a Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma ( NCT05440708 ). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter) .
The company’s own description, as it appears at the foot of the release.
The quote, the company description and the latest quarter come from Tvardi Therapeutics’s earnings press release (an Item 2.02 8-K) filed November 13, 2026. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Read the release on EDGAR Share prices are split- and dividend-adjusted.